Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron versus solifenacin for mixed urinary incontinence in women
IRCT20200402046915N3Phase 4Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mirabegron and solifenacin in Mixed incontinence (MUI) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Change in I-QOL questionnaire score. Started Feb 2026; status: recruiting.
02
Drugs
mirabegronsolifenacin
03
Conditions
Mixed incontinence (MUI)
Beyond the preview
Go deeper on IRCT20200402046915N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200402046915N3.